DrÀgerwerk stock sets EUR 4.5 billion 2030 sales target
Published on 11/21/2026 at 11:36 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWSDrĂ€ger's 2030 strategy takes shape
- DrÀger presented a long-term plan focused on profitable growth in its Medical and Safety divisions.
- The strategy emphasizes integrated solutions, recurring revenue and selected international growth markets.
- Berenberg retained its Buy rating while changing its price target after the strategy presentation.
DrĂ€gerwerk presented its Ambition 2030 plan on Wednesday, November 18, at its first Capital Markets Day in LĂŒbeck. In the EQS announcement published by TradingView News, the medical and safety technology group set a 2030 sales target of EUR 4.5 billion and an EBIT margin target of 10% to 12%.
Growth plans for both divisions
DrÀger expects Medical and Safety to contribute roughly equally to the planned expansion. Medical is set to build on integrated solutions, recurring revenue from its installed base and patient monitoring, with the United States and Asia-Pacific identified as important growth regions.
Safety is focusing on U.S. fire departments, defense, maritime applications, energy transition and cleantech. The company also cited pricing, direct-cost optimization and higher productivity as levers for improved profitability.
The plan preserves a shareholder-return element: DrÀger said it intends to distribute at least 30% of net profit and expects double-digit dividend growth in the coming years. These objectives remain dependent on execution, demand and the group's ability to convert productivity measures into sustainable margins.
Analyst view shifts after strategy day
On Friday, November 20, Berenberg retained its Buy rating and changed its price target from EUR 162 to EUR 156, according to MarketScreener. The move followed the strategy presentation and puts management's long-term targets alongside a more cautious near-term valuation view.
DrÀgerwerk stock closed at EUR 117.00 on Xetra on Friday, November 20, according to MarketScreener. For investors, the next test is whether order growth, pricing and recurring revenue can support the margin path set out for 2030.
DrÀgerwerk stock at a glance
- Company: DrÀgerwerk AG & Co. KGaA
- ISIN: DE0005550636
- Business: Medical and safety technology
- Xetra close: EUR 117.00 on November 20, 2026
- 2030 sales target: EUR 4.5 billion
- 2030 EBIT margin target: 10% to 12%
German equities remain the broader market setting for DrÀgerwerk stock; see Current market reports.
More news and analyses on DrÀgerwerk stock.
